SCHEMBL482254

SCHEMBL482254

CC1=C[N]C(c2ccccc2)=N1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.37
PTGS1 P23219 1/20 0.35
PTGS2 P35354 1/20 0.35
ALDH1A1 P00352 3/20 0.35
CYP2A6 P11509 1/20 0.34
CYP2B6 P20813 1/20 0.34
NPC1 O15118 3/20 0.33
RAB9A P51151 3/20 0.33
MAPK1 P28482 1/20 0.33
TP53 P04637 1/20 0.33
MAPT P10636 1/20 0.33
AKT2 P31751 2/20 0.32
CHEK1 O14757 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
AKT1 P31749 1/20 0.32
BRD4 O60885 1/20 0.32
BRD2 P25440 1/20 0.32
POLB P06746 1/20 0.32
HPGD P15428 1/20 0.32
NFKB1 P19838 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5602505 0.82 TDP1 (0.36) ALDH1A1NPC1RAB9ATP53MAPT
SCHEMBL21151453 0.68 ALDH1A1 (0.53) L3MBTL1ALDH1A1NPC1RAB9AMAPK1
SCHEMBL5044579 0.68 TAAR1 (0.39) ALDH1A1CYP2A6CYP2B6NPC1RAB9A
SCHEMBL7354716 0.68 L3MBTL1 (0.37) L3MBTL1ALDH1A1CYP2A6CYP2B6NPC1
SCHEMBL7009257 0.64
SCHEMBL1435641 0.64 L3MBTL1 (0.37) L3MBTL1ALDH1A1CYP2A6CYP2B6NPC1
Biphenyl SCHEMBL10622486 0.61 ALDH1A1 (0.90) ALDH1A1CYP2A6CYP2B6NPC1RAB9A
Biphenyl SCHEMBL29185389 0.61 ALDH1A1 (0.90) ALDH1A1CYP2A6CYP2B6NPC1RAB9A
Biphenyl SCHEMBL1198500 0.61 ALDH1A1 (0.90) ALDH1A1CYP2A6CYP2B6NPC1RAB9A
Biphenyl SCHEMBL10908072 0.61 ACHE (0.73) L3MBTL1ALDH1A1NPC1RAB9AMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1937669-B9 NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS JANSSEN PHARMACEUTICA NV (BE) 2012-07-18 EP claimed
EP-1937669-B1 NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS JANSSEN PHARMACEUTICA NV (BE) 2012-02-01 EP claimed
CN-101296925-A Novel benzopyran derivatives as potassium channel openers JANSSEN PHARMACEUTICA NV (BE) 2008-10-29 CN claimed
US-7276567-B2 Heterocyclic substituted metallocene compounds for olefin polymerization EXXONMOBIL CHEMICAL PATENTS INC. (US) 2007-10-02 US claimed
US-20070049556-A1 NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS JANSSEN PHARMACEUTICA N.V. (BE) 2007-03-01 US claimed
US-20240109869-A1 CHARGE TRANSFER COMPLEX ADEKA CORPORATION (JP) 2024-04-04 US disclosed
EP-4289821-A1 CHARGE TRANSFER COMPLEX Adeka Corporation (JP) 2023-12-13 EP disclosed
CN-116710436-A Charge transfer complexes 株式会社艾迪科 2023-09-05 CN disclosed
EP-1937669-B9 NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS JANSSEN PHARMACEUTICA NV (BE) 2012-07-18 EP disclosed
EP-1937669-B1 NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS JANSSEN PHARMACEUTICA NV (BE) 2012-02-01 EP disclosed
US-7838553-B2 Benzopyran derivatives as potassium channel openers JANSSEN PHARMACEUTICA NV (BE) 2010-11-23 US disclosed
US-7812183-B2 Benzopyran derivatives as potassium channel openers JANSSEN PHARMACEUTICA NV (BE) 2010-10-12 US disclosed
EP-1940516-A2 BENZOPYRAN AND PYRANOPYRIDINE DERIVATIVES AS POTASSIUM CHANNEL OPENERS Janssen Pharmaceutica, N.V. (BE) 2008-07-09 EP disclosed
EP-1937669-A1 NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS JANSSEN PHARMACEUTICA N.V. (BE) 2008-07-02 EP disclosed
US-7276567-B2 Heterocyclic substituted metallocene compounds for olefin polymerization EXXONMOBIL CHEMICAL PATENTS INC. (US) 2007-10-02 US disclosed
US-20070072832-A1 NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS JANSSEN PHARMACEUTICA N.V. (BE) 2007-03-29 US disclosed
WO-2007027959-A1 NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS JANSSEN PHARMACEUTICA N.V. (BE) 2007-03-08 WO disclosed
WO-2007027780-A2 BENZOPYRAN AND PYRANOPYRIDINE DERIVATIVES AS POTASSIUM CHANNEL OPENERS JANSSEN PHARMACEUTICA N.V. (BE) 2007-03-08 WO disclosed
US-20070049556-A1 NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS JANSSEN PHARMACEUTICA N.V. (BE) 2007-03-01 US disclosed
US-20050261449-A1 Heterocyclic substituted metallocene compounds for olefin polymerization EXXONMOBIL CHEMICAL PATENT INC. 2005-11-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049556-A1 NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS KCNJ2, KCNN1, KCNN3 L3MBTL1 4225/4885PTGS1 1250/4885PTGS2 1149/4885
US-20240109869-A1 CHARGE TRANSFER COMPLEX TRMT1, ELP1, SEM1 L3MBTL1 3287/4885PTGS1 2038/4885PTGS2 2162/4885
US-20070072832-A1 NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS KCNJ2, KCNN1, KCNN3 L3MBTL1 4225/4885PTGS1 1250/4885PTGS2 1149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.